: BPC 157
PMID: 40628573 ) Schol J, Huang IH, Carbone F, Fernandez LMB, Gourcerol G, Ho V, Kohn G, Lacy BE, Colombo AL, Miwa H, Moshiree B, Nguyen L, OGrady G, Siah KTH, Stanghellini V, Tack J (2025) Rome Foundation and international neurogastroenterology and motility societies consensus on idiopathic gastroparesis
10.1345/aph.1E495 9 BoyerJ
Clinical trials have yielded mixed results: several studies, including a phase II trial of NLY01, failed to meet primary endpoints for motor progression, with only modest or nonsignificant effects overall [37,38]
As with many antagonists, resistance is possible
Rather, it just hits the skin cells to halt the exuberant healing response. (As an additional prophylactic measure, Dr